This is not trading/investment advice For good background on the PALISADE trial and Aimmune Therapeutics, check out my prior blog post: https://breakingbiotech.com/2017/10/09/going-nuts-for-oral-immunotherapy-aimt/ -MDGL drop this week on no news is a buying opportunity, if you haven't taken a position -ADMS drop has more merit. I'm waiting to see what they say about this paragraph IV notice https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm047676.htm#p3 -Aimmune Therapeutics shows very solid Phase 3 data for their desensitization therapy and treatment AR101 https://www.aimmune.com/